Bayer, CRISPR Therapeutics Form $335M+ Gene Editing Venture

Dec 21, 2015, 09:14 AM by Michael Croft

Xconomy | Bayer and CRISPR Therapeutics have signed a pact that could be worth more than $335 million to develop CRISPR-based drugs for a variety of diseases starting with blindness, blood disorders, and congenital heart disease.

December 21, 2015 | Bayer and CRISPR Therapeutics have signed a pact that could be worth more than $335 million to develop CRISPR-based drugs for a variety of diseases starting with blindness, blood disorders, and congenital heart disease. Xconomy